Jivandhara Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 03-01-2025
- Paid Up Capital ₹ 0.11 M
as on 03-01-2025
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.55 M
as on 03-01-2025
- Satisfied Charges ₹ 3.07 M
as on 03-01-2025
- Revenue 27.48%
(FY 2022)
- Profit 25.15%
(FY 2022)
- Ebitda 22.32%
(FY 2022)
- Net Worth 15.23%
(FY 2022)
- Total Assets 9.08%
(FY 2022)
About Jivandhara Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹0.55 M. The company has closed loans amounting to ₹3.07 M, as per Ministry of Corporate Affairs (MCA) records.
Manishkumar Desai, Dhiren Kapadia, Vijaykumar Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231GJ2003PTC042633
- Company No.
042633
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Navsari, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Jivandhara Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manishkumar Desai  | Director | 17-Jul-2003 | Current |
| Dhiren Kapadia | Director | 17-Jul-2003 | Current |
| Vijaykumar Patel | Director | 17-Jul-2003 | Current |
| Nimesh Choksi | Director | 17-Jul-2003 | Current |
Financial Performance of Jivandhara Pharma.
Jivandhara Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.48% increase. The company also saw a substantial improvement in profitability, with a 25.15% increase in profit. The company's net worth Soared by an impressive increase of 15.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jivandhara Pharma?
In 2020, Jivandhara Pharma had a promoter holding of 34.26% and a public holding of 65.74%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Aug 2022 | ₹0.55 M | Open |
Others Creation Date: 12 Apr 2019 | ₹0.45 M | Satisfied |
The Gandevi Peoples Co.Op.Bank Ltd. Creation Date: 17 May 2012 | ₹0.12 M | Satisfied |
How Many Employees Work at Jivandhara Pharma?
Unlock and access historical data on people associated with Jivandhara Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jivandhara Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jivandhara Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
